サマリー

神経変性疾患は、神経細胞やそのミエリン鞘が失われ、時間の経過とともに悪化し、機能不全に陥ることで起こります。

市場分析と洞察。神経変性疾患治療薬の世界市場
神経変性疾患治療薬の世界市場規模は、2020年のXX百万米ドルから、2021-2027年の間にXX％のCAGRで、2027年にXX百万米ドルに達すると予測されます。
本レポートは、業界標準の正確な分析と高いデータの整合性により、世界の神経変性疾患治療薬市場で得られる主要な機会を明らかにし、プレイヤーが市場での確固たる地位を獲得するのに役立つよう、見事な試みを行っています。本レポートの購入者は、検証された信頼性の高い市場予測にアクセスすることができ、その中には収益面での世界の神経変性疾患治療薬市場全体のサイズも含まれています。
本レポートは、神経変性疾患治療薬市場において競合他社よりも優位に立ち、永続的な成功を収めるための効果的なツールであることを証明しています。本レポートに掲載されているすべての調査結果、データ、情報は、信頼できる情報源の助けを借りて検証、再検証されています。本レポートを執筆したアナリストは、世界の神経変性疾患治療薬市場を詳細に調査するために、独自の業界最高水準の調査・分析手法を用いています。

世界の神経変性疾患治療薬の範囲と市場規模
神経変性疾患治療薬市場は、企業別、地域（国）別、タイプ別、アプリケーション別に分類されています。世界の神経変性疾患治療薬市場に参加するプレイヤー、ステークホルダー、その他の参加者は、このレポートを強力なリソースとして利用することで、優位に立つことができるでしょう。セグメント別分析では、2016年から2027年の期間で、タイプ別、アプリケーション別の収益と予測に焦点を当てています。

タイプ別セグメント
薬剤クラス別
免疫調整剤（Immunomodulator
インターフェロン
デカルボキシラーゼ阻害剤
ドパミンアゴニスト
その他
投与経路別
経口
注射
経皮

用途別セグメント
多発性硬化症
パーキンソン病
アルツハイマー型認知症
脊髄性筋萎縮症(SMA)
その他

地域別
北アメリカ
米国
カナダ
ヨーロッパ
ドイツ
フランス
イギリス
イタリア
ロシア
北欧
その他のヨーロッパ諸国
アジア太平洋地域
中国
日本
韓国
東南アジア
インド
オーストラリア
その他のアジア諸国
ラテンアメリカ
メキシコ
ブラジル
その他のラテンアメリカ
中近東・アフリカ
トルコ
サウジアラビア
アラブ首長国連邦
その他の中東・アフリカ地域

会社別
バイオジェン
ファイザー
ロシュ
ノバルティス
サノフィ
テバ・ファーマシューティカルズ
Orion Pharma Ltd.
UCB S.A.
アカディア・ファーマシューティカルズ・インク
Lundbeck Pharmaceuticals Italy S.p.A.
田辺三菱製薬アメリカ

ページTOPに戻る

目次

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Neurodegenerative Diseases Drug Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Immunomodulator
1.2.3 Interferons
1.2.4 Decarboxylase Inhibitors
1.2.5 Dopamine Agonists
1.2.6 Others
1.3 Market by Application
1.3.1 Global Neurodegenerative Diseases Drug Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Multiple Sclerosis
1.3.3 Parkinson’s Disease
1.3.4 Alzheimer’s Disease
1.3.5 Spinal Muscular Atrophy (SMA)
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Neurodegenerative Diseases Drug Market Perspective (2016-2027)
2.2 Neurodegenerative Diseases Drug Growth Trends by Regions
2.2.1 Neurodegenerative Diseases Drug Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Neurodegenerative Diseases Drug Historic Market Share by Regions (2016-2021)
2.2.3 Neurodegenerative Diseases Drug Forecasted Market Size by Regions (2022-2027)
2.3 Neurodegenerative Diseases Drug Industry Dynamic
2.3.1 Neurodegenerative Diseases Drug Market Trends
2.3.2 Neurodegenerative Diseases Drug Market Drivers
2.3.3 Neurodegenerative Diseases Drug Market Challenges
2.3.4 Neurodegenerative Diseases Drug Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Neurodegenerative Diseases Drug Players by Revenue
3.1.1 Global Top Neurodegenerative Diseases Drug Players by Revenue (2016-2021)
3.1.2 Global Neurodegenerative Diseases Drug Revenue Market Share by Players (2016-2021)
3.2 Global Neurodegenerative Diseases Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Neurodegenerative Diseases Drug Revenue
3.4 Global Neurodegenerative Diseases Drug Market Concentration Ratio
3.4.1 Global Neurodegenerative Diseases Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Neurodegenerative Diseases Drug Revenue in 2020
3.5 Neurodegenerative Diseases Drug Key Players Head office and Area Served
3.6 Key Players Neurodegenerative Diseases Drug Product Solution and Service
3.7 Date of Enter into Neurodegenerative Diseases Drug Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Neurodegenerative Diseases Drug Breakdown Data by Type
4.1 Global Neurodegenerative Diseases Drug Historic Market Size by Type (2016-2021)
4.2 Global Neurodegenerative Diseases Drug Forecasted Market Size by Type (2022-2027)

5 Neurodegenerative Diseases Drug Breakdown Data by Application
5.1 Global Neurodegenerative Diseases Drug Historic Market Size by Application (2016-2021)
5.2 Global Neurodegenerative Diseases Drug Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Neurodegenerative Diseases Drug Market Size (2016-2027)
6.2 North America Neurodegenerative Diseases Drug Market Size by Type
6.2.1 North America Neurodegenerative Diseases Drug Market Size by Type (2016-2021)
6.2.2 North America Neurodegenerative Diseases Drug Market Size by Type (2022-2027)
6.2.3 North America Neurodegenerative Diseases Drug Market Size by Type (2016-2027)
6.3 North America Neurodegenerative Diseases Drug Market Size by Application
6.3.1 North America Neurodegenerative Diseases Drug Market Size by Application (2016-2021)
6.3.2 North America Neurodegenerative Diseases Drug Market Size by Application (2022-2027)
6.3.3 North America Neurodegenerative Diseases Drug Market Size by Application (2016-2027)
6.4 North America Neurodegenerative Diseases Drug Market Size by Country
6.4.1 North America Neurodegenerative Diseases Drug Market Size by Country (2016-2021)
6.4.2 North America Neurodegenerative Diseases Drug Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Neurodegenerative Diseases Drug Market Size (2016-2027)
7.2 Europe Neurodegenerative Diseases Drug Market Size by Type
7.2.1 Europe Neurodegenerative Diseases Drug Market Size by Type (2016-2021)
7.2.2 Europe Neurodegenerative Diseases Drug Market Size by Type (2022-2027)
7.2.3 Europe Neurodegenerative Diseases Drug Market Size by Type (2016-2027)
7.3 Europe Neurodegenerative Diseases Drug Market Size by Application
7.3.1 Europe Neurodegenerative Diseases Drug Market Size by Application (2016-2021)
7.3.2 Europe Neurodegenerative Diseases Drug Market Size by Application (2022-2027)
7.3.3 Europe Neurodegenerative Diseases Drug Market Size by Application (2016-2027)
7.4 Europe Neurodegenerative Diseases Drug Market Size by Country
7.4.1 Europe Neurodegenerative Diseases Drug Market Size by Country (2016-2021)
7.4.2 Europe Neurodegenerative Diseases Drug Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size (2016-2027)
8.2 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type
8.2.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Type (2016-2027)
8.3 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application
8.3.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Application (2016-2027)
8.4 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region
8.4.1 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Neurodegenerative Diseases Drug Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Neurodegenerative Diseases Drug Market Size (2016-2027)
9.2 Latin America Neurodegenerative Diseases Drug Market Size by Type
9.2.1 Latin America Neurodegenerative Diseases Drug Market Size by Type (2016-2021)
9.2.2 Latin America Neurodegenerative Diseases Drug Market Size by Type (2022-2027)
9.2.3 Latin America Neurodegenerative Diseases Drug Market Size by Type (2016-2027)
9.3 Latin America Neurodegenerative Diseases Drug Market Size by Application
9.3.1 Latin America Neurodegenerative Diseases Drug Market Size by Application (2016-2021)
9.3.2 Latin America Neurodegenerative Diseases Drug Market Size by Application (2022-2027)
9.3.3 Latin America Neurodegenerative Diseases Drug Market Size by Application (2016-2027)
9.4 Latin America Neurodegenerative Diseases Drug Market Size by Country
9.4.1 Latin America Neurodegenerative Diseases Drug Market Size by Country (2016-2021)
9.4.2 Latin America Neurodegenerative Diseases Drug Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size (2016-2027)
10.2 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type
10.2.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Type (2016-2027)
10.3 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application
10.3.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Application (2016-2027)
10.4 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country
10.4.1 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Neurodegenerative Diseases Drug Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Biogen
11.1.1 Biogen Company Details
11.1.2 Biogen Business Overview
11.1.3 Biogen Neurodegenerative Diseases Drug Introduction
11.1.4 Biogen Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.1.5 Biogen Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Details
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Neurodegenerative Diseases Drug Introduction
11.2.4 Pfizer Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.2.5 Pfizer Recent Development
11.3 Roche
11.3.1 Roche Company Details
11.3.2 Roche Business Overview
11.3.3 Roche Neurodegenerative Diseases Drug Introduction
11.3.4 Roche Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.3.5 Roche Recent Development
11.4 Novartis
11.4.1 Novartis Company Details
11.4.2 Novartis Business Overview
11.4.3 Novartis Neurodegenerative Diseases Drug Introduction
11.4.4 Novartis Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.4.5 Novartis Recent Development
11.5 Sanofi
11.5.1 Sanofi Company Details
11.5.2 Sanofi Business Overview
11.5.3 Sanofi Neurodegenerative Diseases Drug Introduction
11.5.4 Sanofi Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.5.5 Sanofi Recent Development
11.6 Teva Pharmaceuticals
11.6.1 Teva Pharmaceuticals Company Details
11.6.2 Teva Pharmaceuticals Business Overview
11.6.3 Teva Pharmaceuticals Neurodegenerative Diseases Drug Introduction
11.6.4 Teva Pharmaceuticals Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.6.5 Teva Pharmaceuticals Recent Development
11.7 Orion Pharma Ltd
11.7.1 Orion Pharma Ltd Company Details
11.7.2 Orion Pharma Ltd Business Overview
11.7.3 Orion Pharma Ltd Neurodegenerative Diseases Drug Introduction
11.7.4 Orion Pharma Ltd Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.7.5 Orion Pharma Ltd Recent Development
11.8 UCB S.A
11.8.1 UCB S.A Company Details
11.8.2 UCB S.A Business Overview
11.8.3 UCB S.A Neurodegenerative Diseases Drug Introduction
11.8.4 UCB S.A Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.8.5 UCB S.A Recent Development
11.9 ACADIA Pharmaceuticals Inc.
11.9.1 ACADIA Pharmaceuticals Inc. Company Details
11.9.2 ACADIA Pharmaceuticals Inc. Business Overview
11.9.3 ACADIA Pharmaceuticals Inc. Neurodegenerative Diseases Drug Introduction
11.9.4 ACADIA Pharmaceuticals Inc. Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.9.5 ACADIA Pharmaceuticals Inc. Recent Development
11.10 Lundbeck Pharmaceuticals Italy S.p.A.
11.10.1 Lundbeck Pharmaceuticals Italy S.p.A. Company Details
11.10.2 Lundbeck Pharmaceuticals Italy S.p.A. Business Overview
11.10.3 Lundbeck Pharmaceuticals Italy S.p.A. Neurodegenerative Diseases Drug Introduction
11.10.4 Lundbeck Pharmaceuticals Italy S.p.A. Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.10.5 Lundbeck Pharmaceuticals Italy S.p.A. Recent Development
11.11 Mitsubishi Tanabe Pharma America
11.11.1 Mitsubishi Tanabe Pharma America Company Details
11.11.2 Mitsubishi Tanabe Pharma America Business Overview
11.11.3 Mitsubishi Tanabe Pharma America Neurodegenerative Diseases Drug Introduction
11.11.4 Mitsubishi Tanabe Pharma America Revenue in Neurodegenerative Diseases Drug Business (2016-2021)
11.11.5 Mitsubishi Tanabe Pharma America Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details